Login to Your Account



Niche HIV drug moves closer to market with phase III hit

By Michael Fitzhugh
Staff Writer

Tuesday, May 24, 2016

Preliminary data from a pivotal phase III test of experimental HIV drug ibalizumab helped 82.5 percent of patients receiving it meet the study's primary endpoint of a decrease of ≥ 0.5 log10 in viral load following a seven-day treatment period.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription